TY - JOUR
T1 - Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research
T2 - Perspectives of Research Needs in Anal Cancer
AU - Guren, Marianne Grønlie
AU - Sebag-Montefiore, David
AU - Franco, Pierfrancesco
AU - Johnsson, Anders
AU - Segelov, Eva
AU - Deutsch, Eric
AU - Rao, Sheela
AU - Spindler, Karen Lise Garm
AU - Arnold, Dirk
N1 - Publisher Copyright:
© 2021
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Anal cancer is a relatively rare, mostly HPV-related cancer. The curative treatment consists of concurrent chemoradiation delivered with modern radiotherapy techniques. The prognosis for most patients with early localized disease is very favourable; however patients with locally advanced disease and/or HPV negative tumours are at higher risk of locoregional and distant treatment failure. Tailored approaches are presently being investigated to determine the most suitable regimen in terms of radiotherapy dose prescription, target volume selection, normal tissue avoidance, and combination therapy. Metastatic anal cancer is treated with chemotherapy aiming at prolonged survival. The role of immune therapy in the clinical setting is being investigated. There is little knowledge on the biology of anal cancer, and an urgent need for more clinical and translational research dedicated to this disease. In this article, the evidence-base for the current treatment is briefly reviewed, and perspectives on future research needs are high-lighted.
AB - Anal cancer is a relatively rare, mostly HPV-related cancer. The curative treatment consists of concurrent chemoradiation delivered with modern radiotherapy techniques. The prognosis for most patients with early localized disease is very favourable; however patients with locally advanced disease and/or HPV negative tumours are at higher risk of locoregional and distant treatment failure. Tailored approaches are presently being investigated to determine the most suitable regimen in terms of radiotherapy dose prescription, target volume selection, normal tissue avoidance, and combination therapy. Metastatic anal cancer is treated with chemotherapy aiming at prolonged survival. The role of immune therapy in the clinical setting is being investigated. There is little knowledge on the biology of anal cancer, and an urgent need for more clinical and translational research dedicated to this disease. In this article, the evidence-base for the current treatment is briefly reviewed, and perspectives on future research needs are high-lighted.
KW - Chemotherapy
KW - Human papilloma virus
KW - Immune checkpoint inhibition
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85116913841&partnerID=8YFLogxK
U2 - 10.1016/j.clcc.2021.09.006
DO - 10.1016/j.clcc.2021.09.006
M3 - Comment/debate
C2 - 34645589
AN - SCOPUS:85116913841
SN - 1533-0028
VL - 20
SP - 279
EP - 287
JO - Clinical Colorectal Cancer
JF - Clinical Colorectal Cancer
IS - 4
ER -